- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Value Key in Oncology Care
For oncologists and other cancer care specialists, value-based care is essential.
For oncologists and other cancer care specialists, value-based care is essential. Experts who gathered at the 50th annual meeting of The American Society of Clinical Oncology (ASCO) this past week learned that value-based care focuses both on cost and quality—and for good reason.
“The problem is that the current system is unsustainable because it threatens access to high-quality cancer care,” said Neal Meropol, MD, FASCO, chief of hematology and oncology at University Hospitals Case Medical Center in Cleveland.
ASCO is currently developing a system which can rate and compare cancer treatments according to their cost, benefits, and side effects. Understanding the cost versus benefit of each drug is important for insurance companies as much as it is for providers and patients.
“The stakeholders need to work together to find solution(s), to drive policy, and achieve reform,” added Dr Meropol.
Presenters at ASCO recognized that variation in quality standards can harm patient outcomes. They also noted that current health models fail to address challenges such as inefficient use of resources and health inequalities. The value framework could educate stakeholders by increasing transparency about cancer treatment options.
Value is not just a goal in the United States either.
“All healthcare systems are struggling to deliver affordable and equitable cancer care,” said Richard Sullivan, MD, PhD, from the Kings Health Partners Integrated Cancer Centre in London, England. “Our global economic systems have become addicted to the returns generated by cancer care and treatment.”
Like ASCO, the European Society for Medical Oncology (ESMO) has begun to develop a system which will rate cancer drugs based on a scale. Those treatments with the highest-scaled value will be promoted with the hope of standardizing quality and easing patients’ access to certain drugs. Groups such as ASCO and ESMO play an essential role in establishing cancer treatment guidelines that ensure patients have access to value-based care.
Around the Web
Cancer Doctors Urged to Consider Value When Treating Patients [Reuters]
How Do You Establish Value in Cancer Care? [AJMC]
The Oncologist Defines ‘Value of Care’ [AJMC]
More Care Doesn't Equal Happier Patients in Traditional Medicare
March 17th 2025Data on care satisfaction, ease managing care, and out-of-pocket spending were the outcomes of interest for this new analysis that investigated the relationship between healthcare utilization and beneficiary experience within traditional Medicare.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
